[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100081216":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":18,"locations":23,"responsibleParty":41,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":7,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":7,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Iowa","OTHER",null,[9,12,16],{"name":10,"affiliation":5,"role":11},"Katherine Mathews, M.D.","PRINCIPAL_INVESTIGATOR",{"name":13,"affiliation":14,"role":15},"Kevin Campbell, Ph.D.","Co-Investigator","STUDY_DIRECTOR",{"name":17,"affiliation":14,"role":15},"Steven A. Moore, M.D. Ph.D.",[19],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":7},"Carrie Stephan, R.N. M.A.","CONTACT","(319) 356-2673",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University of Iowa, 200 Hawkins Drive","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-91.53017,41.66113,{"lat":36,"lon":35},[39],{"name":20,"role":21,"phone":40,"phoneExt":7,"email":7},"(319)356-2673",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Katherine Mathews","Professor and Principal Investigator",[46],{"name":47,"class":48},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100081216","clinical-trial-readiness-for-the-dystroglycanopathies-100081216",false,"NCT00313677","Clinical Trial Readiness for the Dystroglycanopathies","Inclusion Criteria:\n\n* Elevated CK (creatine kinase)\n* Evidence of a dystroglycanopathy as determined by review of muscle pathology OR documented mutation in one of the known genes OR abnormal alpha-dystroglycan glycosylation in cultured fibroblasts\n* Dystroglycanopathies are predicted to affect all racial and ethnic backgrounds, and all patients with dystroglycanopathies will be eligible for participation.\n* Participants may be of any age, including children, and males and females will be recruited equally.\n* Patients will have varying degrees of muscular weakness, but otherwise should be in relatively good health.\n\nExclusion Criteria:\n\n* There are no exclusion criteria.","ALL",{"count":57,"type":58},190,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.",[62],"Muscular Dystrophy",[64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91],"muscular dystrophy","MD","fukutin-related protein gene","limb girdle","FKRP gene","congenital muscular dystrophy","childhood onset LGMD","adult onset LGMD","POMT1","POMT2","POMGnT1","LARGE","alpha dystroglycan","dystroglycanopathy","ISPD\u002FCRPPA","DPM 1, 2 or 3","GMPPB","B3GNT1\u002FB4GAT1","B3GALNT2","GTDC2\u002FPOMGnT2","TMEM5\u002FRXYLT1","Fukutin","DAG1","POMK\u002FSGK196","DOLK","TRAPPC11","GOSR2","INPP5K","2025-07-24",{"date":94,"type":95},"2025-07-30","ACTUAL",{"date":97,"type":7},"2006-04",{"date":99,"type":58},"2030-07",{"name":43,"class":6},1]